Abstract:The last 20 years have witnessed dramatic reductions in cardiovascular risk using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") to lower levels of low-density lipoprotein cholesterol (LDL-C). Using this approach one can achieve a reduction in the risk of major cardiovascular events of 21% for every 1 mmol/l (39 mg/dl) decrease in LDL-C. However, despite intensive therapy with high dose "statins" to lower LDL-C levels below 2.6 mmol/l (100 mg/dl), the risk of a major cardiovascular event in patients with established coronary artery disease remains significant at a level approaching an annual risk of 9%, paving the way for new strategies for reducing the residual cardiovascular risk in this patient group. Early epidemiological studies have identified low levels of high-density lipoprotein cholesterol (HDL-C) (<1.0 mmol/l or 40 mg/dl), a common feature of type 2 diabetes mellitus and the metabolic syndrome, to be an independent determinant of increased cardiovascular risk. The beneficial effects of HDL-C on the cardiovascular system have been attributed to its ability to remove cellular cholesterol, as well as its anti-inflammatory, antioxidant and antithrombotic properties, which act in concert to improve endothelial function and inhibit atherosclerosis, thereby reducing cardiovascular risk. As such, raising HDL-C in patients with aggressively lowered LDL-C provides an additional strategy for addressing the residual cardiovascular risk present in these patients groups. Studies suggest that for every 0.03 mmol/l (1.0 mg/dl) increase in HDL-C, cardiovascular risk is reduced by 2-3%. Raising HDL-C can be achieved by both lifestyle changes and pharmacological means, the former of which include smoking cessation, aerobic exercise, weight loss and dietary manipulation. Therapeutic strategies have included niacin, fibrates, thiazolidinediones and bile acid sequestrants. Newly developed pharmacological agents include apolipoprotein A-I mimetics and the cholesteryl ester transfer protein (CETP) inhibitors, JTT-705 and torcetrapib, the latter of which has been recently withdrawn from clinical testing because of serious adverse effects. Emerging experimental studies investigating the complex pathways of HDL metabolism have identified several new targets for raising HDL-C with new pharmaceutical agents currently in development. For the time being, the long-acting formulations of nicotinic acid remain the most effective and best tolerated pharmacological strategy for raising HDL-C in patients already on statin therapy to control LDL-C. Therefore, raising HDL-C represents an important strategy for reducing residual cardiovascular risk in patients already optimally treated with statins, and should lead to further improvements in clinical outcomes in these patient groups.

The Therapy of Low Levels of High Density Lipoprotein-Cholesterol

[Investigation on Levels of Serum Lipids among 602 Patients Who Had Undergone Coronary Angiography in Zheijian Province].

Study of hypo-high-density-lipoproteinemia and coronary artery lesions in patients with coronary heart disease

Advances in Research on the Inhibitors of High Density Lipoprotein Cholesteryl Ester Transfer Protein and Its Mechanism

High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases

[Association of High-Density Lipoprotein Cholesterol with Risk of Cardiovascular Disease Mortality].

Relationship between high density lipoprotein-cholesterol level and coronary heart disease in Chinese Han population

EFFECT OF HORMONE REPLACEMENT THERAPY ON SERUM LIPOPROTEIN AND APOLIPOPROTEIN

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.

Rational regards on high-density lipoprotein

LIPID MANAGEMENT IN ACUTE CORONARY SYNDROME PATIENTS AMONG THE TIER THREE HOSPITALS

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels

An Association Study of Lipoprotein and Apolipoprotein Levels in the Coronary Heart Disease

Identifying the natural products in the treatment of atherosclerosis by increasing HDL-C level based on bioinformatics analysis, molecular docking, and in vitro experiment

High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?

Assessment of the application of non-high-density lipoprotein cholesterol in coronary artery disease

Targeting high-density lipoproteins: update on a promising therapy

Contemporary Management And Attainment Of Cholesterol Targets For Patients With Dyslipidemia In China

Factors Influencing Low-Density Lipoprotein Cholesterol Target Achievement in Primary Care - Results from DYSIS China.

Association of the Low-Density Lipoprotein Cholesterol/high-Density Lipoprotein Cholesterol Ratio and Concentrations of Plasma Lipids with High-Density Lipoprotein Subclass Distribution in the Chinese Population

High-Density Lipoprotein and Heart Failure